Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft

NCT00067041 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT00067041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00067041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo-Controlled, 12-Week Multicenter Study of the Safety and Efficacy of Remodulin in Patients With Critical Limb Ischemia Following an Autogenous Vein Infrainguinal Bypass Graft
Lead sponsor
United Therapeutics
Phase
Phase 2/3
Overall status
Terminated
Start date
March 31, 2003
Completion date
December 31, 2003
Enrollment
30
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral vascular disease